Abstract

The San Francisco Vaccine and Prevention Unit (SFVPU) provides scientific leadership, capacity to recruit study volunteers into vaccine and non-vaccine prevention trials, innovative methods for community engagement in research, and mentorship of junior investigators. We will test vaccine and prevention strategies likely to have the greatest impact in reducing HIV infection in the United States and globally through our affiliation with the HIV Vaccine Trials Network and the HIV Prevention Trials Network. The SFVPU is housed in the San Francisco Department of Public Health, using a non-profit fiscal pass-through agency, Public Health Foundation Enterprises, to provide fiscal and human-resource management. ADMINISTRATIVE COMPONENT:

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI069496-03S2
Application #
7900165
Study Section
Special Emphasis Panel (ZAI1-AR-A (M1))
Program Officer
Sachau, Bill R
Project Start
2009-09-01
Project End
2012-08-31
Budget Start
2009-09-01
Budget End
2012-08-31
Support Year
3
Fiscal Year
2009
Total Cost
$2,521,856
Indirect Cost

  Institution

Name
Public Health Foundation Enterprises
Department
Type
DUNS #
082199324
City
City of Industry
State
CA
Country
United States
Zip Code
91746

  Publications

Jalil, Emilia M; Grinsztejn, Beatriz; Velasque, Luciane et al. (2018) Awareness, Willingness, and PrEP Eligibility Among Transgender Women in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 79:445-452
Anderson, Peter L; Liu, Albert Y; Castillo-Mancilla, Jose R et al. (2018) Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother 62:
Tang, Eric C; Vittinghoff, Eric; Anderson, Peter L et al. (2018) Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. J Acquir Immune Defic Syndr 77:193-198
Glidden, David V; Mulligan, Kathleen; McMahan, Vanessa et al. (2018) Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clin Infect Dis 67:411-419
Fuchs, Jonathan D; Stojanovski, Kristefer; Vittinghoff, Eric et al. (2018) A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. AIDS Patient Care STDS 32:104-111
Latkin, Carl A; Van Tieu, Hong; Fields, Sheldon et al. (2017) Social Network Factors as Correlates and Predictors of High Depressive Symptoms Among Black Men Who Have Sex with Men in HPTN 061. AIDS Behav 21:1163-1170
Janes, Holly E; Cohen, Kristen W; Frahm, Nicole et al. (2017) Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. J Infect Dis 215:1376-1385
Levy, Matthew E; Phillips 2nd, Gregory; Magnus, Manya et al. (2017) A Longitudinal Analysis of Treatment Optimism and HIV Acquisition and Transmission Risk Behaviors Among Black Men Who Have Sex with Men in HPTN 061. AIDS Behav 21:2958-2972
Glidden, David V; Mulligan, Kathleen; McMahan, Vanessa et al. (2017) Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. J Acquir Immune Defic Syndr 76:177-182
Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60

Showing the most recent 10 out of 40 publications